Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.
Separately, Wall Street Zen cut shares of Cumberland Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of "Sell".
View Our Latest Research Report on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Stock Performance
NASDAQ:CPIX traded up $0.11 during trading hours on Wednesday, reaching $3.67. The company had a trading volume of 45,156 shares, compared to its average volume of 28,221. The company has a current ratio of 1.30, a quick ratio of 1.17 and a debt-to-equity ratio of 0.19. Cumberland Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $7.25. The firm has a market cap of $54.90 million, a price-to-earnings ratio of -16.68 and a beta of -0.41. The firm's 50 day moving average price is $3.30 and its 200-day moving average price is $4.02.
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported $0.02 EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 6.97% and a positive return on equity of 7.48%.
Institutional Trading of Cumberland Pharmaceuticals
Several institutional investors have recently modified their holdings of the stock. Bridgeway Capital Management LLC lifted its stake in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company's stock worth $631,000 after buying an additional 4,200 shares in the last quarter. XTX Topco Ltd purchased a new position in Cumberland Pharmaceuticals during the second quarter worth about $34,000. Heron Bay Capital Management purchased a new position in Cumberland Pharmaceuticals during the second quarter worth about $111,000. Adage Capital Partners GP L.L.C. purchased a new position in Cumberland Pharmaceuticals during the first quarter worth about $634,000. Finally, Walleye Capital LLC purchased a new position in Cumberland Pharmaceuticals during the first quarter worth about $298,000. Institutional investors and hedge funds own 15.51% of the company's stock.
Cumberland Pharmaceuticals Company Profile
(
Get Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.